VivoSim Labs, Inc. (VIVS) Key Metrics
VIVS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.6M
- Enterprise value
- $1.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 23.2
- Price / book
- 0.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.49
VIVS key metrics, FY2017–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsVIVS returns How much profit the business earns on the capital it uses.
Return on assets−101.9 pts
−125.6%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover−13.3%
0.01
FY2026 · hover or tap a bar for each year
FY2017FY2026
VIVS financial health Debt, liquidity and how easily interest is covered.
Net debt+$5.8M
−$4.6M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio−26.7%
2.38
FY2026 · hover or tap a bar for each year
FY2017FY2026
Debt / assets−5.9%
0.06
FY2026 · hover or tap a bar for each year
FY2017FY2026
VIVS efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+1,419 days
1,499 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Capex / revenue−9.0 pts
0.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
VIVS returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VIVS debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VIVS cash returned to shareholders
DividendsBuybacksFree cash flow
VIVS key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $1.43 | $2.24 | $12.36 | $26.28 | $45.12 | $115.68 | $98.40 | $237.60 | $247.20 | $763.20 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −35.3% | −155.0% | −75.8% | −33.0% | −51.1% | −59.5% | −65.9% | −65.1% | −61.7% |
| Return on invested capital (ROIC) | — | −899.5% | −740.0% | −578.3% | −326.8% | — | — | — | — | — |
| Return on assets (ROA) | −125.6% | −23.7% | −110.1% | −64.4% | −31.3% | −49.2% | −54.2% | −58.9% | −58.5% | −56.2% |
| Return on tangible assets | −187.4% | −17.0% | −231.1% | −85.0% | −34.4% | −42.2% | −65.8% | −65.6% | −69.8% | −55.6% |
| Free cash flow margin | — | — | — | — | −590.8% | — | −677.7% | −661.7% | −633.3% | −722.0% |
| Financial health | ||||||||||
| Total debt | $447,000 | $942,000 | $1.4M | $1.8M | $2.2M | — | — | — | — | — |
| Cash & short-term investments | $5.0M | $11.3M | $2.9M | $16.0M | $28.7M | $37.4M | $27.4M | $36.5M | $43.7M | $62.8M |
| Net debt | −$4.6M | −$10.4M | −$1.5M | −$14.2M | −$26.5M | −$37.4M | −$27.4M | −$36.5M | −$43.7M | −$62.8M |
| Debt / equity | — | 0.09 | 0.39 | 0.12 | 0.07 | — | — | — | — | — |
| Debt / assets | 0.06 | 0.06 | 0.22 | 0.09 | 0.07 | — | — | — | — | — |
| Current ratio | 2.38 | 3.25 | 2.12 | 4.64 | 21.35 | 53.26 | 15.65 | 10.32 | 10.04 | 10.83 |
| Quick ratio | 2.38 | 3.25 | 1.96 | 4.64 | 21.35 | 53.26 | 15.65 | 10.19 | 9.86 | 10.74 |
| Interest coverage | -935.3 | — | — | — | — | — | — | — | — | — |
| Working capital | $3.8M | $8.4M | $2.1M | $13.4M | $28.1M | $37.7M | $26.5M | $34.8M | $42.1M | $59.1M |
| Invested capital | −$5.7M | $122,000 | $2.1M | $1.1M | $3.7M | $1.8M | −$725,000 | −$179,000 | $860,000 | −$389,000 |
| Tangible asset value | −$1.1M | $10.5M | $3.6M | $15.3M | $30.2M | $39.2M | $26.6M | $36.3M | $44.6M | $62.4M |
| Net current asset value | −$1.9M | $8.0M | $1.2M | $12.1M | $26.4M | $37.7M | $26.5M | $34.2M | $41.5M | $58.3M |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | $0 | $1,000 | — | — | — | — |
| Capex / revenue | 0.0% | 9.0% | 38.5% | 107.0% | 27.3% | — | 0.0% | 2.6% | 6.4% | 32.0% |
| Capex / depreciation | 0.00 | 0.05 | 0.15 | 1.35 | 2.88 | 9.88 | 0.00 | 0.08 | 0.23 | 1.18 |
| Stock-based compensation / revenue | 231.3% | 369.4% | 1,383.5% | 642.4% | 150.4% | — | 187.1% | 168.0% | 150.0% | 174.8% |
| R&D / revenue | 3,197.7% | 3,489.6% | 5,044.0% | 2,401.4% | 221.3% | — | 240.6% | 477.3% | 390.1% | 462.1% |
| SG&A / revenue | 5,470.2% | 5,341.0% | 8,847.7% | 2,456.2% | 642.1% | — | 781.0% | 475.6% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 1,499.0 | 79.8 | 309.7 | 75.0 | 0.0 | — | 55.6 | 93.6 | 66.4 | 39.1 |
| Days of inventory on hand | — | — | — | — | — | — | — | 504.3 | 246.6 | 168.8 |
| Days payables outstanding | — | 82,891.5 | — | — | — | — | 750.0 | 413.5 | 289.7 | 373.8 |
| Cash conversion cycle (days) | — | -71,971.2 | — | — | — | — | -694.4 | 184.5 | 23.4 | -165.9 |
| Receivables turnover | 0.24 | 4.57 | 1.18 | 4.87 | — | 0.00 | 6.57 | 3.90 | 5.50 | 9.34 |
| Payables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.49 | 0.88 | 1.26 | 0.98 |
| Inventory turnover | — | — | 0.00 | — | — | — | — | 0.72 | 1.48 | 2.16 |
| Asset turnover | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.00 | 0.06 | 0.07 | 0.08 | 0.06 |
| Average receivables | $538,000 | $31,500 | $92,500 | $76,000 | $0 | $55,500 | $334,500 | $793,000 | $837,500 | $453,000 |
| Average payables | $1.3M | $1.1M | $479,000 | $373,000 | $348,000 | $500,500 | $674,000 | $546,000 | $817,500 | $979,000 |
| Average inventory | — | $148,500 | $148,500 | $0 | — | — | — | $666,000 | $696,000 | $442,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VIVS's annual financial statements (latest annual report filed July 14, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VIVS valuation and financial ratios
It ended the year with $0.4 million of debt and $5.0 million in cash and short-term investments, a net cash position of $4.6 million.
See the VIVS income statement, the VIVS chart for price history, or the VIVS stock overview for the latest quote and news.
VIVS key metrics FAQ
How much debt does VivoSim Labs have?
VivoSim Labs had total debt of $0.4 million at the end of fiscal 2026 and more cash than debt.
What is VivoSim Labs's current ratio?
VivoSim Labs's current ratio was 2.38 at the end of fiscal 2026: current assets were 2.38 times current liabilities.